Clinical research is changing faster than ever before. With digital tools, remote monitoring, and global participation becoming the new standard, it’s clear that the ethical foundation of clinical trials needs to evolve. The International Council for Harmonisation (ICH) recognised this reality and, in January 2025, released the updated ICH E6 (R3) — Good Clinical Practice (GCP) guideline.
Unlike the earlier versions that focused mostly on operational compliance, E6 (R3) brings ethics, participant protection, and data integrity to the forefront. It recognises that good science and good ethics are inseparable — and that both depend on trust, transparency, and accountability.
One of the most noticeable changes is how the guideline replaces the term “human subjects” with “trial participants.” This isn’t just a language tweak. It signals a major shift in how research views people — not as test subjects, but as active contributors whose rights, safety, and well-being must always come before the interests of science. It sets the tone for a more humane, participant-centric approach to clinical trials.
A major update comes in how informed consent is handled. ICH E6 (R3) embraces the digital age, officially recognising electronic consent (eConsent) as a valid and ethical way for participants to understand and agree to their involvement. The new approach also treats consent as a continuous conversation, not a one-time signature. Participants must have the freedom to ask questions, revisit information, and withdraw whenever they choose. For global and decentralised trials, where participants may never meet the investigator in person, this change ensures clarity and autonomy. It also highlights the importance of using accessible language, visual aids, and interactive tools that help people truly understand what they’re agreeing to.
Beyond participant protection, E6 (R3) builds a stronger system for data integrity — a crucial aspect in today’s digital trials. Modern research collects data from apps, sensors, electronic health records, and remote devices. To keep this data reliable and transparent, the guideline introduces stricter rules for data governance. Every piece of data must be traceable from its origin to its final submission. Metadata — like timestamps, user IDs, and device logs — must be maintained to prove authenticity. And even when sponsors use third-party service providers or CROs, the responsibility for data accuracy and participant confidentiality still lies with the sponsor.
This update recognises that in the digital era, protecting data is part of protecting participants. A breach in data integrity isn’t just a technical issue; it’s an ethical one. Reliable data ensures that medical decisions, regulatory approvals, and scientific conclusions are based on truth.
The role of Ethics Committees (IRBs/IECs) also expands under E6 (R3). They’re now expected to review not just traditional study designs but also digital platforms, apps, and data systems used in trials. They must ensure that remote or decentralised studies still meet the same ethical standards as in-person ones. Importantly, committees are encouraged to review trials continuously — not only at the beginning — especially when new technologies or procedures are introduced mid-study.
At its core, the new guideline is about transparency, traceability, and trust. Transparency ensures that participants know how their data is being used. Traceability guarantees that every action taken in the trial can be verified. And trust — between participants, investigators, and regulators — is what keeps the entire system credible.
For professionals entering the field of clinical research, these updates aren’t just regulatory details. They represent a new mindset. The modern CRA or CRC must understand ethics as deeply as data. They must think critically about risk, quality, and participant experience — not just follow checklists. ICH E6 (R3) encourages a balance between human values and scientific rigor, and this will shape the future of how trials are conducted around the world.
Ultimately, ICH E6 (R3) isn’t simply an update to Good Clinical Practice. It’s a re-imagining of what “good” really means — good for science, and good for the people behind it. By humanising research participants and modernising data management, the guideline ensures that ethical excellence remains the foundation of every clinical discovery.
As the world moves deeper into decentralised and data-driven medicine, one truth remains unchanged: ethical research begins and ends with respect for the individual.
- AI